Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Alyeska Investment Group increased its Dianthus Therapeutics position by 188.2% in the second quarter, acquiring 98,345 additional shares and bringing its holdings to 150,592 shares valued at $14.68 million.
• Dianthus shares opened at $105.61, near their 52-week high, while the company reported a quarterly loss of $0.90 per share—worse than analyst expectations—despite revenue exceeding estimates.
• Wall Street maintains a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $124.27; however, company insiders sold more than 260,000 shares worth $27.2 million during the quarter.

Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 188.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,592 shares of the company's stock after buying an additional 98,345 shares during the period. Alyeska Investment Group L.P. owned 0.28% of Dianthus Therapeutics worth $14,680,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DNTH. ABS Investment Management LLC bought a new position in shares of Dianthus Therapeutics in the second quarter worth about $194,960,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter valued at approximately $32,000. EFG International AG bought a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $49,000. Global Retirement Partners LLC acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $93,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $40,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Down 0.2%

DNTH opened at $105.61 on Tuesday. The stock's 50 day simple moving average is $103.96 and its 200-day simple moving average is $87.71. The stock has a market cap of $5.77 billion, a PE ratio of -25.45 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1 year low of $22.81 and a 1 year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial restated a "strong-buy" rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Dianthus Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $124.27.

Insider Buying and Selling

In other news, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares in the company, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anne Mcgeorge sold 7,750 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. The trade was a 86.11% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 260,554 shares of company stock worth $27,211,775. Insiders own 3.02% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source